Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma LSE:IMM London Ordinary Share GB0033711010 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +8.50p +5.04% 177.00p 178.50p 181.00p 184.50p 173.00p 173.00p 1,565,583 16:35:14
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.2 -6.3 -4.5 - 234.57

Immupharma (IMM) Latest News

More Immupharma News
Immupharma Takeover Rumours

Immupharma (IMM) Share Charts

1 Year Immupharma Chart

1 Year Immupharma Chart

1 Month Immupharma Chart

1 Month Immupharma Chart

Intraday Immupharma Chart

Intraday Immupharma Chart

Immupharma (IMM) Discussions and Chat

Immupharma Forums and Chat

Date Time Title Posts
20/1/201822:10IMMUPHARMA - IN FINAL PHASE 3 LUPUS TRIAL TARGETING BLOCKBUSTER ($1bn+) REVENUES10,411
18/1/201820:33ImmuPharma - Global Potential Blockbusters & Huge Potential Upside83
04/1/201807:22cockerspaniel-
09/10/201707:08Sell order-
07/10/201710:31exciting times -

Add a New Thread

Immupharma (IMM) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Immupharma trades in real-time

Immupharma (IMM) Top Chat Posts

DateSubject
20/1/2018
08:20
Immupharma Daily Update: Immupharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker IMM. The last closing price for Immupharma was 168.50p.
Immupharma has a 4 week average price of 148p and a 12 week average price of 82.50p.
The 1 year high share price is 193p while the 1 year low share price is currently 44p.
There are currently 132,522,985 shares in issue and the average daily traded volume is 782,032 shares. The market capitalisation of Immupharma is £234,565,683.45.
12/1/2018
18:51
englishlongbow: Reputable analysts tend to be deliberately 'conservative' and undervalue stocks in research notes, to allow share prices to then excede their estimates. Real world figures are a better guide: 1) IMM's Chairman, Tim McCarthy, has said quite unequivocally that Lupuzor will be a multi-billion dollar drug and they could target 1.5 million to 2 million patients at $25k+ a year (and analyst VA has said as much as $40k to $50k pa). 40,000 patients at $25,000 pa = $1 billion pa revenue 50,000 patients at $25,000 pa = $1.25 billion pa revenue 100,000 patients at $25,000 pa = $2.5 billion pa revenue 150,000 patients at $25,000 pa = $3.75 billion pa revenue 250,000 patients at $25,000 pa = $6.25 billion pa revenue 500,000 patients at $25,000 pa = $12.5 billion pa revenue 750,000 patients at $25,000 pa = $18.75 billion pa revenue 1,000,000 patients at $25,000 pa = $25 billion pa revenue 1,250,000 patients at $25,000 pa = $31.25 billion pa revenue 1,500,000 patients at $25,000 pa = $37.5 billion pa revenue 2) PeptideDream is valued at $4 billion just on a few deals, one platform and without anything in Phases 2 or 3, or on the market; whereas IMM have one drug in Phase 2 and one near end of Phase 3 (blockbuster Lupuzor) plus two platforms and 7 drugs in total. Parity with PeptideDream's $4 bn market capitalisation puts IMM's share price at £22. 3) HGSi's Benlysta was effectively valued at $7 billion in the takeover by GSK, and seems to be inferior to IMM's Lupuzor, and is not part of a wider platform unlike Lupuzor. Parity with Benlysta's $7 bn valuation puts IMM's share price at £40. 4) Gilhead took over Kite in 2017 for $11.9 billion on predicted AxiCel sales of $1.7 pa billion by 2022 and some say it was actually for the platform not the near-term revenues - IMM have two platforms, including P140 which is applicable to 9+ high value indications. Parity with Kite's $11.9 bn buyout puts IMM's share price at £68.
12/1/2018
14:52
englishlongbow: Reputable analysts tend to be deliberately 'conservative' and undervalue stocks in research notes, to allow share prices to then excede their estimates. Real world figures are a better guide: 1) IMM's Chairman, Tim McCarthy, has said quite unequivocally that Lupuzor will be a multi-billion dollar drug and they could target 1.5 million to 2 million patients at $25k+ a year (and analyst VA has said as much as $40k to $50k pa). 2) PeptideDream is valued at $4 billion just on a few deals, one platform and without anything in Phases 2 or 3, or on the market; whereas IMM have one drug in Phase 2 and one near end of Phase 3 (blockbuster Lupuzor) plus two platforms and 7 drugs in total. Parity with PeptideDream's $4 bn market capitalisation puts IMM's share price at £22. 3) HGSi's Benlysta was effectively valued at $7 billion in the takeover by GSK, and seems to be inferior to IMM's Lupuzor, and is not part of a wider platform unlike Lupuzor. Parity with Benlysta $7 bn valuation puts IMM's share price at £40. 4) Gilhead took over Kite in 2017 for $11.9 billion on predicted AxiCel sales of $1.7 pa billion by 2022 and some say it was actually for the platform not the near-term revenues - IMM have two platforms, including P140 which is applicable to 9+ high value indications. Parity with Kite's $11.9 bn buyout puts IMM's share price at £68.
31/12/2017
14:08
hamhamham1: runt. The IMM share price is going to hit £100. We are all going to be millionaires. There you go :)
31/12/2017
11:44
stanman: Personally I welcome njb's contributions with their dose of caution and realism. As a retired clinician who was involved just a little with drug trial work (mainly to do with the early days of statins, and in some endocrine-related areas) I really do think that some of the IMM share price forecasts here verge on the ludicrous! There are major hurdles still to negotiate with the P3 trial etc.... etc.... but like others of course I hope for the very best of outcomes, as a LTH.But to talk of share price valuations of £100 is ridiculous IMHO. That would give IMM a market cap equivalent to a company just short of the top third of the FTSE-100. No, it will not be like that. A price of £5? I will be delighted. GLA.
12/12/2017
15:51
hottingup: There is a small pull back on every rise but the rise is now the trend. On the basis we assume Lupuzor passes Phase 3 in Q1 2018 then any valuation of Lupuzor / P140 must start as a minimum with the $3.6 billion paid in 2012 by GSK to acquire HGSi's 50% stake in lupus drug Benlysta - effectively valuing 100% of Benlysta at $7 billion - equating to an IMM share price around £40. To that $7 billion (£40) should then be added something for inflation during what in 2018 will then be the last 6 years since 2012; Lupuzor (I assume) being more efficaceous, having less or no side effects and being cheaper to produce, than Benlysta; use in other indications (including off label and on label) some of which have market sizes many times larger than for lupus; new patent granted to 2032 in key countries (USA, EU, China, India and Japan) covering Lupuzor and its use in the treatment of the majority of autoimmune diseases such as Sjogrens syndrome, rheumatoid arthritis, Crohn's, CIDP, Guillan-Barre disease (announced 27/9/2017); and a new patent recently filed (2017) to cover non-autoimmune indications. Consequently the value of Lupuzor in Q1 2018 should be much higher than $7 billion (potentially multiples) and the share price much higher than £40. N.B. Lupuzor Symposium 8th June 2016 - 3:35 pm 41 min 40 sec onwards - hTTps://player.vimeo.com/video/170358317 Data from IMM suggests Lupuzor / P140 may be able to treat several blockbuster autoimmune and non-autoimmune diseases, including: - Systemic Lupus Erythematosus (SLE) (Market size $4 bn) (SLE ends Phase 3, Q1 2018) - Neuropsychiatric lupus (NPSLE) - Gougerot-Sjögren syndrome (GSS) (Market size $2.2 bn by 2024) - Rheumatoid Arthritis (Market size $28.5 bn by 2025) - Gougerot-Sjögren syndrome (GSS) (Market size $2.2 bn by 2024) - Crohn's Disease + Ulcerative Colitis (Market size $4 bn by 2022) - Guillan-Barre disease - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Asthma (Market size $20.7 bn in 2015) Other potential evaluations: - Scleroderma (Systemic Sclerosis, Raynaud) - Psoriasis - Multiple Sclerosis (MS) (Market size $20 bn by 2024) Negative preclinical results for potential re-evaluation: - Type I Diabetes (Market size $43 bn by 2021) - Amytrophic Lateral Sclerosis (ALS)
12/12/2017
14:49
top tips: Shares magazine Why the drug space is looking more attractive Shares in parts of the sector are rising and there is a rich stream of news flow in the coming months Thur 26 Oct 2017 Author: Lisa-Marie Janes hTTps://www.youinvest.co.uk/sharesmagazine/2017-10-26/why-the-drug-space-is-looking-more-attractive It has been a volatile few years for the healthcare industry with several headwinds acting as a drag on performance, including the threat of drug pricing caps and healthcare reform in the US. Is life now getting better? The NASDAQ Biotech index in early October traded at its highest level since December 2015. On the UK stock market, shares in many drug makers have been in a rising trend since late summer 2017. Panmure Gordon has even upgraded its stance on the pharmaceuticals, biotechnology and healthcare sector to ‘positive’, believing the next nine months to be a strong period for UK life science company news. ‘Multiple significant trial readouts are expected, companies are generally well funded and many of the headwinds seen in previous quarters are easing,’ says analyst Julie Simmonds. Trump turns attention to tax Simmonds believes many headwinds that dragged on the performance of the overall sector such as the attempt to repeal the Affordable Care Act in the US and drug pricing pressures are easing. ‘Healthcare reform in the US is moving to the back burner to be replaced by tax reform, which could have a more positive outcome for the sector,’ says the analyst. The pressure on pharmaceutical companies to cut drug prices has receded as an immediate threat, but Simmonds flags companies will need to remain conscious on prices at launch and if they choose to hike prices. This could lead to a more imaginative approach to pricing such as patients not paying if the drug is not effective within a specific time period. What's happening with UK-listed drug companies? Simmonds believes ‘rapidly moving technologies’ are behind the positive performance of parts of the UK quoted healthcare sector, pointing to upcoming Phase III results from firms such as ImmuPharma (IMM:AIM). ImmuPharma is undergoing its Phase III trial for lead treatment Lupuzor with results expected in the first quarter of 2018. Lupuzor is anticipated to have blockbuster potential and is considered safer and more effective than GlaxoSmithKline’s (GSK) Benlysta. The drug treats lupus by modifying the behaviour of certain key cells involved in the development of the disease, which can be fatal as it causes the body to make antibodies that attack healthy tissue. Shares in ImmuPharma have nearly doubled in price this year to 97p as investors anticipate positive results from the study. More stocks with legs Pharmaceutical products developer Silence Therapeutics (SLN:AIM) has also had a good year thanks to moves in the RNAi sector, according to Simmonds. RNA is short for ribonucleic acid, which is a linear molecule that can play an important role in cells such as switching genes on and off. RNA interference (RNAi) is used to study gene function by enabling gene expression and targeting only problematic genes that cause the disease. Simmonds flags several catalysts behind Silence’s share price surge, including US listed Alnylam’s Phase III results for its patisiran to treat a rare nerve disorder and positive news on Spark Therapeutics’ therapy Luxturna. Shares in Quantum Pharma (QP.:AIM) have had a good run this year thanks to a takeover offer by Clinigen (CLIN:AIM). What news will continue to drive a strong performance? One of the key catalysts for any company working in the biopharma industry are trial readouts, specifically Phase III results. A strong outcome can lead to approval from healthcare authorities. These include the US Food and Drug Administration or European Medicines Agency. In the run up to results, investors tend to jump on the bandwagon and ride the share price momentum. There are several Phase III results expected in the next nine months, with some expected as early as the first quarter of 2018. These include ImmuPharma, Faron Pharmaceutical’s (FARN:AIM) Traumakine treatment for acute respiratory distress syndrome and Shield Therapeutics’ (STX:AIM) Feraccru for treating iron deficiency anaemia. In the first half of 2018, Phase III results are also anticipated from Diurnal (DNL:AIM) for its cortisol replace product Chronocort. (LMJ)
05/12/2017
14:05
money maker1: hamhamham you seem to have misunderstood the GSK HGSi deal and my valuation. GSK bought HGSi in 2012 for $3.6 billion, to get HGSi's 50% stake in their lupus drug Benlysta. That effectively valued 100% of Benlysta at $7.2 billion, or call it $7 billion because HGSi also had a few other drugs in the pipeline. £7 billion roughly equates to an IMM share price of £40. However the expectation is that IMM's Lupuzor will be more efficaceous and safer than Benlysta, making it worth more than Benlysta. In addition there is evidence Lupuzor should be able to treat several other high value indications, also making it worth more than Benlysta. Consequently I suggest a value for IMM, if Lupuzor passses Phase 3 for lupus and could be used in at least five other indications, of £60 to £100.
04/12/2017
15:44
hottingup: On the basis we assume Lupuzor passes Phase 3 in Q1 2018 then any valuation of Lupuzor / P140 must start as a minimum with the $3.6 billion paid in 2012 by GSK to acquire HGSi's 50% stake in lupus drug Benlysta - effectively valuing 100% of Benlysta at $7 billion - equating to an IMM share price around £40. To that $7 billion (£40) should then be added something for inflation during what in 2018 will then be the last 6 years since 2012; Lupuzor (I assume) being more efficaceous, having less or no side effects, being cheaper to produce and more comfortable to administer, than Benlysta; use in other multiple indications (including off label and on label) some of which have market sizes many times larger than for lupus; new patent granted to 2032 in key countries (USA, EU, China, India and Japan) covering Lupuzor and its use in the treatment of the majority of autoimmune diseases such as Sjogrens syndrome, rheumatoid arthritis, Crohn's, CIDP, Guillan-Barre disease (announced 27/9/2017); and a new patent recently filed (2017) to cover non-autoimmune indications. Consequently the value of Lupuzor in Q1 2018 should be much higher than $7 billion (potentially multiples) and the share price much higher than £40. N.B. Lupuzor™ Symposium 8th June 2016 - 3:35 pm 41 min 40 sec onwards - hTTps://player.vimeo.com/video/170358317 Data from IMM suggests Lupuzor / P140 may be able to treat several blockbuster autoimmune and non-autoimmune diseases, including: - Systemic Lupus Erythematosus (SLE) (Market size $4 bn) (SLE ends Phase 3, Q1 2018) - Neuropsychiatric lupus (NPSLE) - Gougerot-Sjögren syndrome (GSS) (Market size $2.2 bn by 2024) - Rheumatoid Arthritis (Market size $28.5 bn by 2025) - Gougerot-Sjögren syndrome (GSS) (Market size $2.2 bn by 2024) - Crohn's Disease + Ulcerative Colitis (Market size $4 bn by 2022) - Guillan-Barre disease - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Asthma (Market size $20.7 bn in 2015) Other potential evaluations: - Scleroderma (Systemic Sclerosis, Raynaud) - Psoriasis - Multiple Sclerosis (MS) (Market size $20 bn by 2024) Negative preclinical results for potential re-evaluation: - Type I Diabetes (Market size $43 bn by 2021) - Amytrophic Lateral Sclerosis (ALS)
21/11/2017
10:14
hottingup: On the basis we assume Lupuzor passes Phase 3 in Q1 2018 then any valuation of Lupuzor / P140 must start as a minimum with the $3.6 billion paid in 2012 by GSK to acquire HGSi's 50% stake in lupus drug Benlysta - effectively valuing 100% of Benlysta at $7 billion - equating to an IMM share price around £40. To that $7 billion (£40) should then be added something for inflation during what in 2018 will then be the last 6 years since 2012; Lupuzor (I assume) being more efficaceous, having less or no side effects, being cheaper to produce and more comfortable to administer, than Benlysta; use in other multiple indications (including off label and on label) some of which have market sizes many times larger than for lupus; new patent granted to 2032 in key countries (USA, EU, China, India and Japan) covering Lupuzor and its use in the treatment of the majority of autoimmune diseases such as Sjogrens syndrome, rheumatoid arthritis, Crohn's, CIDP, Guillan-Barre disease (announced 27/9/2017); and a new patent recently filed (2017) to cover non-autoimmune indications. Consequently the value of Lupuzor in Q1 2018 should be much higher than $7 billion (potentially multiples) and the share price much higher than £40. N.B. Data from IMM suggests Lupuzor / P140 may be able to treat several blockbuster autoimmune and non-autoimmune diseases, including: - Systemic Lupus Erythematosus (SLE) (Market size $4 bn) - Neuropsychiatric lupus (NPSLE) - Gougerot-Sjögren syndrome (GSS) (Market size $2.2 bn by 2024) - Rheumatoid Arthritis (Market size $28.5 bn by 2025) - Gougerot-Sjögren syndrome (GSS) (Market size $2.2 bn by 2024) - Crohn's Disease + Ulcerative Colitis (Market size $4 bn by 2022) - Guillan-Barre disease - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Asthma (Market size $20.7 bn in 2015) Other potential evaluations: - Scleroderma (Systemic Sclerosis, Raynaud) - Psoriasis - Multiple Sclerosis (MS) (Market size $20 bn by 2024) Negative preclinical results for potential re-evaluation: - Type I Diabetes (Market size $43 bn by 2021) - Amytrophic Lateral Sclerosis (ALS)
15/11/2017
11:59
hottingup: On the basis we assume Lupuzor passes Phase 3 in Q1 2018 then any valuation of Lupuzor / P140 must start as a minimum with the $3.6 billion paid in 2012 by GSK to acquire HGSi's 50% stake in lupus drug Benlysta - effectively valuing 100% of Benlysta at $7 billion - equating to an IMM share price around £40. To that $7 billion (£40) should then be added something for inflation during what in 2018 will then be the last 6 years since 2012; Lupuzor (I assume) being more efficaceous, having less or no side effects, being cheaper to produce and more comfortable to administer, than Benlysta; use in other multiple indications (including off label and on label) some of which have market sizes many times larger than for lupus; new patent granted to 2032 in key countries (USA, EU, China, India and Japan) covering Lupuzor and its use in the treatment of the majority of autoimmune diseases such as Sjogrens syndrome, rheumatoid arthritis, Crohn's, CIDP, Guillan-Barre disease (announced 27/9/2017); and a new patent recently filed (2017) to cover non-autoimmune indications. Consequently the value of Lupuzor in Q1 2018 should be much higher than $7 billion (potentially multiples) and the share price much higher than £40.
Immupharma share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V: D:20180120 22:37:56